Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and
EpiCept Corporation (“EpiCept”) (NASDAQ OMX Stockholm Exchange and OTCQX: EPCT)
today announced that they have entered into a definitive merger agreement. The
transaction is anticipated to close during the first quarter of 2013 and is
subject to satisfaction of certain customary closing conditions, including the
approval of a majority of EpiCept shareholders.
